» Articles » PMID: 19005780

Creatine and Its Potential Therapeutic Value for Targeting Cellular Energy Impairment in Neurodegenerative Diseases

Overview
Specialty Biochemistry
Date 2008 Nov 14
PMID 19005780
Citations 68
Authors
Affiliations
Soon will be listed here.
Abstract

Substantial evidence indicates bioenergetic dysfunction and mitochondrial impairment contribute either directly and/or indirectly to the pathogenesis of numerous neurodegenerative disorders. Treatment paradigms aimed at ameliorating this cellular energy deficit and/or improving mitochondrial function in these neurodegenerative disorders may prove to be useful as a therapeutic intervention. Creatine is a molecule that is produced both endogenously, and acquired exogenously through diet, and is an extremely important molecule that participates in buffering intracellular energy stores. Once creatine is transported into cells, creatine kinase catalyzes the reversible transphosphorylation of creatine via ATP to enhance the phosphocreatine energy pool. Creatine kinase enzymes are located at strategic intracellular sites to couple areas of high energy expenditure to the efficient regeneration of ATP. Thus, the creatine kinase/phosphocreatine system plays an integral role in energy buffering and overall cellular bioenergetics. Originally, exogenous creatine supplementation was widely used only as an ergogenic aid to increase the phosphocreatine pool within muscle to bolster athletic performance. However, the potential therapeutic value of creatine supplementation has recently been investigated with respect to various neurodegenerative disorders that have been associated with bioenergetic deficits as playing a role in disease etiology and/or progression which include; Alzheimer's, Parkinson's, amyotrophic lateral sclerosis (ALS), and Huntington's disease. This review discusses the contribution of mitochondria and bioenergetics to the progression of these neurodegenerative diseases and investigates the potential neuroprotective value of creatine supplementation in each of these neurological diseases. In summary, current literature suggests that exogenous creatine supplementation is most efficacious as a treatment paradigm in Huntington's and Parkinson's disease but appears to be less effective for ALS and Alzheimer's disease.

Citing Articles

Spirulina Used as Functional Feed Supplement or Alternative Protein Source: A Review of the Effects of Different Dietary Inclusion Levels on Production Performance, Health Status, and Meat Quality of Broiler Chickens.

Lestingi A, Alagawany M, Cerbo A, Crescenzo G, Zizzadoro C Life (Basel). 2025; 14(12.

PMID: 39768246 PMC: 11679488. DOI: 10.3390/life14121537.


Emerging Biomarkers in Metabolomics: Advancements in Precision Health and Disease Diagnosis.

Vo D, Trinh K Int J Mol Sci. 2024; 25(23).

PMID: 39684900 PMC: 11642057. DOI: 10.3390/ijms252313190.


Illustrate the metabolic regulatory mechanism of Taohong Siwu decoction in ischemic stroke by mass spectrometry imaging.

Wang X, Zhang X, Zhang J, Yang H, Liu Z, Peng D Anal Bioanal Chem. 2024; 416(29):6931-6944.

PMID: 39467910 DOI: 10.1007/s00216-024-05591-4.


Elucidating the Antiglycation Effect of Creatine on Methylglyoxal-Induced Carbonyl Stress In Vitro.

Koike S, Mitsuhashi H, Kishida A, Ogasawara Y Int J Mol Sci. 2024; 25(20).

PMID: 39456665 PMC: 11506949. DOI: 10.3390/ijms252010880.


The metabolic signature of blood lipids: a causal inference study using twins.

Wang Y, Liu S, Cao W, Lv J, Yu C, Huang T J Lipid Res. 2024; 65(9):100625.

PMID: 39303494 PMC: 11437770. DOI: 10.1016/j.jlr.2024.100625.


References
1.
Juhn M, Tarnopolsky M . Potential side effects of oral creatine supplementation: a critical review. Clin J Sport Med. 1999; 8(4):298-304. DOI: 10.1097/00042752-199810000-00007. View

2.
Benzi G, Ceci A . Creatine as nutritional supplementation and medicinal product. J Sports Med Phys Fitness. 2001; 41(1):1-10. View

3.
van der Knaap M, Verhoeven N, Pouwels P, Onkenhout W, Peeters E, Stockler-Ipsiroglu S . Mental retardation and behavioral problems as presenting signs of a creatine synthesis defect. Ann Neurol. 2000; 47(4):540-3. DOI: 10.1002/1531-8249(200004)47:4<540::aid-ana23>3.3.co;2-b. View

4.
Gallant M, Rak M, Szeghalmi A, Del Bigio M, Westaway D, Yang J . Focally elevated creatine detected in amyloid precursor protein (APP) transgenic mice and Alzheimer disease brain tissue. J Biol Chem. 2005; 281(1):5-8. DOI: 10.1074/jbc.C500244200. View

5.
Shefner J, Cudkowicz M, Schoenfeld D, Conrad T, Taft J, Chilton M . A clinical trial of creatine in ALS. Neurology. 2004; 63(9):1656-61. DOI: 10.1212/01.wnl.0000142992.81995.f0. View